Vertex Pharmaceuticals swung to a profit and logged higher sales in the second quarter, as more people used its cystic-fibrosis drug and the biotechnology company began rolling out new therapies.

Vertex Pharmaceuticals' stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into advanced testing. Shares slid 14% to $407.30.

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...